MX2020013122A - Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47). - Google Patents

Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47).

Info

Publication number
MX2020013122A
MX2020013122A MX2020013122A MX2020013122A MX2020013122A MX 2020013122 A MX2020013122 A MX 2020013122A MX 2020013122 A MX2020013122 A MX 2020013122A MX 2020013122 A MX2020013122 A MX 2020013122A MX 2020013122 A MX2020013122 A MX 2020013122A
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
antibodies against
antibodies
ceacam5
against ceacam5
Prior art date
Application number
MX2020013122A
Other languages
English (en)
Inventor
Klaus Strein
Vanessa Buatois
Sara Majocchi
Original Assignee
Lamkap Bio Beta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lamkap Bio Beta Ltd filed Critical Lamkap Bio Beta Ltd
Publication of MX2020013122A publication Critical patent/MX2020013122A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona los anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano CEACAM5 y CD47 humano, los polinucleótidos que codifican tales anticuerpos biespecíficos y los vectores y las células hospedadoras que comprenden tales polinucleótidos. La invención proporciona además los métodos para seleccionar y producir tales anticuerpos y los métodos para usar tales anticuerpos en el tratamiento de enfermedades en monoterapia así como en combinación.
MX2020013122A 2018-06-03 2019-05-31 Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47). MX2020013122A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18175658 2018-06-03
EP18175656 2018-06-03
EP18175655 2018-06-03
EP18175657 2018-06-03
EP18188788 2018-08-13
EP18188790 2018-08-13
EP18188792 2018-08-13
EP18190983 2018-08-27
PCT/IB2019/054559 WO2019234576A1 (en) 2018-06-03 2019-05-31 Bispecific antibodies against ceacam5 and cd47

Publications (1)

Publication Number Publication Date
MX2020013122A true MX2020013122A (es) 2021-04-13

Family

ID=66752156

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013122A MX2020013122A (es) 2018-06-03 2019-05-31 Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47).

Country Status (10)

Country Link
US (3) US20210221908A1 (es)
EP (1) EP3802599B1 (es)
JP (1) JP7403479B2 (es)
KR (1) KR20210029158A (es)
CN (1) CN112566938A (es)
AU (1) AU2019281358A1 (es)
CA (1) CA3102398A1 (es)
ES (1) ES2973518T3 (es)
MX (1) MX2020013122A (es)
WO (1) WO2019234576A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210029158A (ko) 2018-06-03 2021-03-15 람카프 바이오 베타 엘티디. Ceacam5 및 cd47에 대한 이중특이성 항체
EP3831849A1 (en) * 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
IL293926A (en) * 2019-12-17 2022-08-01 Pfizer Antibodies unique to d47, pd-l1 and their uses
CN111018969A (zh) * 2019-12-27 2020-04-17 上海药明生物技术有限公司 采用轻链select联合层析色谱纯化双特异性抗体的方法
ES2967381T3 (es) 2020-12-18 2024-04-30 Lamkap Bio Beta Ag Anticuerpos biespecíficos contra CEACAM5 y CD47
KR20220125394A (ko) 2021-03-05 2022-09-14 주식회사 엘지에너지솔루션 전지 팩 및 이를 포함하는 디바이스
IL305828A (en) * 2021-03-22 2023-11-01 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
CN115819596A (zh) * 2021-09-17 2023-03-21 优迈生物科技(连云港)有限公司 一种靶向人ceacam5/6的抗体、制备方法和应用
WO2023070353A1 (en) * 2021-10-27 2023-05-04 Adagene Pte. Ltd. Anti-cd47 antibodies and methods of use thereof
US20240002544A1 (en) * 2022-03-07 2024-01-04 Novimmune Sa Cd28 bispecific antibodies for targeted t cell activation
WO2023242351A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE458007T1 (de) 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
WO2003056914A1 (en) 2001-12-27 2003-07-17 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures
WO2002030078A1 (fr) 2000-10-05 2002-04-11 Matsushita Electric Industrial Co., Ltd. Procede d'initialisation et emetteur de donnees
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020165360A1 (en) 2000-11-30 2002-11-07 Junghans Richard P. Chimeric effector cell receptors against carcinoembryonic antigen
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
WO2003084570A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
SI1539966T1 (sl) 2002-09-12 2010-10-29 Greenovation Biotech Gmbh Postopek za produkcijo proteinov
JP4559358B2 (ja) 2002-12-20 2010-10-06 グリーンオベーション バイオテク ゲーエムベーハー コケ細胞における異種グリコシル化タンパク質の産生
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
AU2004205802B2 (en) 2003-01-22 2009-11-05 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
AU2003265522A1 (en) 2003-08-18 2005-03-10 Macrogenics, Inc. FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2005056759A2 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005110474A2 (en) 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN101987870B (zh) 2004-07-15 2013-07-03 赞科股份有限公司 优化的Fc变体
CA2577370A1 (en) 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
CN101213297B (zh) 2005-05-09 2013-02-13 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
ES2526811T3 (es) 2005-08-10 2015-01-15 Macrogenics, Inc. Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
EP1945666B1 (en) 2005-10-21 2013-03-27 GTC Biotherapeutics, Inc. Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US8394926B2 (en) 2005-12-21 2013-03-12 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA
EP1999470A4 (en) 2006-03-10 2009-08-19 Macrogenics Inc IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
IL177158A0 (en) 2006-07-30 2008-01-20 Assaf Klar Method for designing and implementing improved longitudinal flexibility multilayered pipeline
ES2457072T3 (es) 2006-08-14 2014-04-24 Xencor, Inc. Anticuerpos optimizados que seleccionan como diana CD19
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
WO2008121160A2 (en) 2006-11-21 2008-10-09 Xencor, Inc. Optimized antibodies that target cd5
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
WO2008091798A2 (en) 2007-01-22 2008-07-31 Xencor, Inc. Optimized ca9 antibodies and methods of using the same
WO2008091954A2 (en) 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2008098115A2 (en) 2007-02-07 2008-08-14 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
PT2520590T (pt) 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Domínio de ligação específico de espécies cruzadas
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
MX2009010611A (es) 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
ES2659517T3 (es) 2007-05-30 2018-03-16 Xencor, Inc. Métodos y composiciones para inhibir células que expresan CD32B
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
HUE034465T2 (en) 2008-02-11 2018-02-28 Cure Tech Ltd Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
EP2703415B1 (en) 2008-09-17 2019-03-06 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
EP2352763B2 (en) 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
CA2738565C (en) 2008-10-01 2023-10-10 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
PT2606064E (pt) 2010-08-16 2015-06-08 Novimmune Sa Processos para a geração de anticorpos poliespecíficos e polivalentes
EA029300B1 (ru) 2011-03-02 2018-03-30 Роше Гликарт Аг Антитело к связанному с мембраной человеческому карциноэмбриональному антигену, его получение и применение
WO2013012414A1 (en) 2011-07-18 2013-01-24 Medimmune, Llc Dosing regimens for treatment of cea-expressing cancers
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
AU2012351751B2 (en) 2011-10-19 2017-09-07 Novimmune S.A. Methods of purifying antibodies
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
BR122022015975B1 (pt) 2012-05-15 2024-01-02 Bristol-Myers Squibb Company Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo
KR20150064068A (ko) * 2012-10-08 2015-06-10 로슈 글리카트 아게 2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법
SI3199552T1 (sl) 2012-11-20 2020-06-30 Sanofi Protitelesa proti-CEACAM5 in njihove uporabe
CA2892585C (en) * 2012-12-03 2022-07-05 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
MY192312A (en) 2013-02-26 2022-08-17 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
ES2898627T3 (es) 2013-04-29 2022-03-08 Univ Leland Stanford Junior Uso de agentes anti-CD47 para mejorar la inmunización
CA2920113A1 (en) 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
WO2015105995A2 (en) 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
EP3096782A4 (en) 2014-01-21 2017-07-26 Medlmmune, LLC Compositions and methods for modulating and redirecting immune responses
US20160009805A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CN107206103A (zh) 2015-01-23 2017-09-26 赫利克斯生物药品公司 用于治疗目的的抗体‑脲酶缀合物
CN107743495B (zh) * 2015-03-23 2021-05-14 拜耳制药股份公司 抗ceacam6抗体及其用途
DK3277821T3 (da) 2015-03-31 2019-10-28 Novimmune Sa Fremgangsmåde til optimering af samling og produktion af hetero-multimere proteinkomplekser
DE102015212888A1 (de) 2015-07-09 2017-01-12 BSH Hausgeräte GmbH Geschirrspülmaschine mit einer Trocknungseinrichtung
SG10201912905VA (en) * 2015-08-07 2020-02-27 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
CR20180162A (es) 2015-10-02 2018-05-25 Hoffmann La Roche Moléculas biespecíficas de unión a antígeno activadoras de células t
EP3165536A1 (en) 2015-11-09 2017-05-10 Ludwig-Maximilians-Universität München Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition
GB2546072B (en) 2016-01-05 2019-07-10 Bja Trading Ltd Attachment assembly and method of using same
AU2017205089B2 (en) 2016-01-08 2023-10-05 F. Hoffmann-La Roche Ag Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
ES2796378T3 (es) * 2016-01-11 2020-11-26 Forty Seven Inc Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos
US20200255515A1 (en) 2016-05-09 2020-08-13 Celgene Corporation Cd47 antibodies and methods of use thereof
CN107556386A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
GB201611530D0 (en) * 2016-07-01 2016-08-17 Alligator Bioscience Ab Novel polypeptides
WO2018098384A1 (en) * 2016-11-22 2018-05-31 Regents Of The University Of California Segregation modulation for immunotherapy
KR20210029158A (ko) 2018-06-03 2021-03-15 람카프 바이오 베타 엘티디. Ceacam5 및 cd47에 대한 이중특이성 항체
ES2967381T3 (es) * 2020-12-18 2024-04-30 Lamkap Bio Beta Ag Anticuerpos biespecíficos contra CEACAM5 y CD47

Also Published As

Publication number Publication date
US20200123252A1 (en) 2020-04-23
EP3802599B1 (en) 2023-12-20
AU2019281358A1 (en) 2021-01-07
CA3102398A1 (en) 2019-12-12
KR20210029158A (ko) 2021-03-15
US11555071B2 (en) 2023-01-17
WO2019234576A1 (en) 2019-12-12
ES2973518T3 (es) 2024-06-20
CN112566938A (zh) 2021-03-26
US20210221908A1 (en) 2021-07-22
JP2021525544A (ja) 2021-09-27
EP3802599C0 (en) 2023-12-20
JP7403479B2 (ja) 2023-12-22
EP3802599A1 (en) 2021-04-14
US20240084001A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
MX2020013122A (es) Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47).
PH12020551211A1 (en) Antibodies binding to gprc5d
MY194642A (en) Antibodies binding to cd3
MX2022003110A (es) Anticuerpos biespecificos contra ceacam5 y cd3.
CR20220019A (es) Anticuerpos que se fijan a gprc5d
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
CL2019001535A1 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza.
PH12020551997A1 (en) Psma binding agents and uses thereof
PH12018500634A1 (en) Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
MY200602A (en) Antibodies against tim3 and uses thereof
PH12019500152A1 (en) Anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
PH12019502755A1 (en) Antibodies that specifically bind pd-1 and methods of use
MX2017006571A (es) Moleculas de union a antigeno biespecificas activadoras de celulas t.
PH12016502505A1 (en) Bispecific t cell activating antigen binding molecules
TN2018000325A1 (en) ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALL Y BINDING TO CD3 AND/OR CD123.
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
MX2022007635A (es) Anticuerpos que se unen a hla-a2/mage-a4.
MX2023007220A (es) Anticuerpos biespecificos contra el antigeno carcinoembrionario humano (ceacam5) y el cumulo de diferenciacion 47 (cd47).
PH12020550952A1 (en) Antibodies binding to hla-a2/wt1
PH12019502274A1 (en) Antibodies binding to steap-1
MX2022015203A (es) Moleculas de union al dominio fc de activacion inmunitaria.
CR20220637A (es) Anticuerpos que se unen a cd3 y cd19
MX2022015204A (es) Anticuerpos que se unen a cd3.
MX2021000783A (es) Anticuerpos humanizados contra psma.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.